within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03H_Antiandrogens.G03HA01_Cyproterone;

model Cyproterone
  extends Pharmacolibrary.Drugs.ATC.G.G03HA01;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>G03HA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cyproterone is a steroidal anti-androgen and progestogen, primarily used to treat androgen-dependent conditions such as prostate cancer, severe hirsutism, and in some cases, as part of hormone therapy for transgender women. It is also used in some countries for the treatment of hypersexuality in men. Its use is more limited today due to safety concerns, including potential for hepatotoxicity.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy male volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Kuhnz, W, et al., &amp; Jütting, G (1993). Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles. <i>Contraception</i> 48(6) 557–575. DOI:<a href=&quot;https://doi.org/10.1016/0010-7824(93)90118-q&quot;>10.1016/0010-7824(93)90118-q</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8131397/&quot;>https://pubmed.ncbi.nlm.nih.gov/8131397</a></p></li><li><p>Hümpel, M, et al., &amp; Speck, U (1977). Bioavailability and pharmacokinetics of cyproterone acetate after oral administration of 2.0 mg cyproterone acetate in combination with 50 micrograms ethinyloestradiol to 6 young women. <i>Contraception</i> 15(5) 579–588. DOI:<a href=&quot;https://doi.org/10.1016/0010-7824(77)90108-1&quot;>10.1016/0010-7824(77)90108-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/880829/&quot;>https://pubmed.ncbi.nlm.nih.gov/880829</a></p></li><li><p>Speck, U, et al., &amp; Jentsch, D (1976). Bio-availability and pharmacokinetics of cyproterone acetate-14C and ethinyloestradiol-3H after oral administration as a coated tablet (SH B 209 AB). <i>Contraception</i> 14(2) 151–163. DOI:<a href=&quot;https://doi.org/10.1016/0010-7824(76)90083-4&quot;>10.1016/0010-7824(76)90083-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/949892/&quot;>https://pubmed.ncbi.nlm.nih.gov/949892</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cyproterone;
